Search Within

David Hyman

  1. "Annals of Oncology"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (7)
  3. Editorial (1)
Groups
  1. Department of Medicine (22)
  2. Early Drug Development Service (22)
  3. Solid Tumor Oncology Division (22)
  4. Thoracic Oncology (11)
  5. GSK Faculty (8)
  6. Human Oncology and Pathogenesis Program (8)

More Groups

People
  1. Alexander Drilon (11)
  2. Alison Schram (5)
  3. David Solit (4)
  4. Marc Ladanyi (4)
  5. Michael Berger (4)
  6. Nikolaus Schultz (4)

More People

Years
  1. 2020 (2)
  2. 2019 (13)
  3. 2018 (1)
  4. 2017 (2)
  5. 2016 (3)
  6. 2014 (1)
Publications
  1. Annals of Oncology (22)
Publishers
  1. Oxford University Press (22)

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization of on-target adverse events caused by TRK inhibitor therapy
    Journal Article

    Liu, D.; Flory, J.; Lin, A.; Offin, M.; Falcon, C. J.; Murciano-Goroff, Y. R.; Rosen, E.; Guo, R.; Basu, E.; Li, B. T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
    Journal Article

    Ross, D. S.; Liu, B.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
    Meeting Abstract

    Ziegler, D. S.; Doz, F.; Geoerger, B.; Dubois, S.; Grilley-Olson, J. E.; van Tilburg, C.; Italiano, A.; Lissat, A.; Kang, J. H.; Tahara, M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
    Meeting Abstract

    Hyman, D.; Tan, D. S. W.; van Tilburg, C.; Albert, C.; Geoerger, B.; Farago, A.; Laetsch, T.; Kummar, S.; Doz, F.; Lassen, U.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Foreword
    Editorial

    Hyman, D. M.; Ladanyi, M.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
    Meeting Abstract

    Italiano, A.; Nanda, S.; Keating, K.; Childs, B. H.; Fellous, M.; Drilon, A.; Hyman, D. M.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
    Meeting Abstract

    Hyman, D. M.; Tan, D. S. W.; van Tilburg, C. M.; Albert, C. M.; Geoerger, B.; Farago, A. F.; Laetsch, T. W.; Kummar, S.; Doz, F.; Lassen, U. N.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
    Meeting Abstract

    Schram, A. M.; Drilon, A.; Macarulla Mercade, T.; O'Reilly, E. M.; Rodon, J. A.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C. H.; Lam, Y. C. J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase II study of olaparib in previously treated advanced solid tumours with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
    Meeting Abstract

    Hyman, D.; Hendifar, A.; Cheol Chung, H.; Maio, M.; Leary, A.; Spanggaard, I.; Rhee, J.; Marton, M.; Chen, M.; Krishnan, S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
    Meeting Abstract

    Drilon, A.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.; Zhu, V.; Camidge, R. D.; Stopatschinskaja, S.; Cui, J. J.; Hyman, D. M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save